BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
dasatinib
Resistant: A2 - Guideline
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Chronic Myeloid Leukemia
CML
|
bosutinib
Resistant: A2 - Guideline
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Chronic Myeloid Leukemia
CML
|
dasatinib
Resistant: A2 - Guideline
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
bosutinib
Resistant: A2 - Guideline
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Chronic Myeloid Leukemia
CML
|
nilotinib
Sensitive: D – Preclinical
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
crizotinib
Sensitive: D – Preclinical
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
GSK1363089
Sensitive: D – Preclinical
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
cabozantinib capsule
Sensitive: D – Preclinical
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
vandetanib
Sensitive: D – Preclinical
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Chronic Myeloid Leukemia
CML
|
imatinib
Sensitive: D – Preclinical
|
